open access

Vol 80, No 7 (2009)
ARTICLES
Get Citation

Evaluation of carbetocin (Pabal) efficacy in the prevention of the postpartum hemorrhage in women after cesarean section – preliminary report

Paweł Krajewski, Maria Prośniewska, Marcin Serafin, Michał Skoczylas, Wojciech Wiliński, Dariusz Sosnowski, Małgorzata Lipińska, Jarosław Kalinka, Tadeusz Laudański
Ginekol Pol 2009;80(7).

open access

Vol 80, No 7 (2009)
ARTICLES

Abstract

Abstract Objectives: The aim of this study was to evaluate the efficacy of carbetocin in prevention of PPH in women after cesarean section. Material and Methods: We enrolled 60 patients who had undergone cesarean section in tertiary referential center, Department of Perinatology, Medical University of Lodz, Poland, between January and June 2008. Each patient obtained a single 100μg dose of carbetocin intravenously during cesarean section, immediately after the delivery of the baby and prior to the delivery of the placenta . We evaluated postoperative blood parameters in 2 and 12 hours after the operation, the proportion of patients requiring additional uterotonic agents and adverse events in the whole population and in the group of women with high risk of PPH. Results: 58.1% of patients underwent emergency and 41.3% elective cesarean section delivery. The risk factor of PPH was identified in 38 women (63.3%). The results of this study indicate that carbetocin produces rapid and longlasting uterine tone. A small drop in mean hemoglobin and hematocrit levels 2 and 12 hours after the operation was observed. 15% of patients required the use of additional uterotonic agents. In the group of women with high risk of PPH, carbetocin appeared to be effective in 79% of the patients. Only 11.4% of patients had minor adverse events. Conclusions: Carbetocin appears to be an effective new drug in the prevention of postpartum hemorrhage, not only among women undergoing cesarean section but also in the group of women with PPH risk factors.

Abstract

Abstract Objectives: The aim of this study was to evaluate the efficacy of carbetocin in prevention of PPH in women after cesarean section. Material and Methods: We enrolled 60 patients who had undergone cesarean section in tertiary referential center, Department of Perinatology, Medical University of Lodz, Poland, between January and June 2008. Each patient obtained a single 100μg dose of carbetocin intravenously during cesarean section, immediately after the delivery of the baby and prior to the delivery of the placenta . We evaluated postoperative blood parameters in 2 and 12 hours after the operation, the proportion of patients requiring additional uterotonic agents and adverse events in the whole population and in the group of women with high risk of PPH. Results: 58.1% of patients underwent emergency and 41.3% elective cesarean section delivery. The risk factor of PPH was identified in 38 women (63.3%). The results of this study indicate that carbetocin produces rapid and longlasting uterine tone. A small drop in mean hemoglobin and hematocrit levels 2 and 12 hours after the operation was observed. 15% of patients required the use of additional uterotonic agents. In the group of women with high risk of PPH, carbetocin appeared to be effective in 79% of the patients. Only 11.4% of patients had minor adverse events. Conclusions: Carbetocin appears to be an effective new drug in the prevention of postpartum hemorrhage, not only among women undergoing cesarean section but also in the group of women with PPH risk factors.
Get Citation

Keywords

carbetocin, postpartum hemorrhage, uterine intertia

About this article
Title

Evaluation of carbetocin (Pabal) efficacy in the prevention of the postpartum hemorrhage in women after cesarean section – preliminary report

Journal

Ginekologia Polska

Issue

Vol 80, No 7 (2009)

Bibliographic record

Ginekol Pol 2009;80(7).

Keywords

carbetocin
postpartum hemorrhage
uterine intertia

Authors

Paweł Krajewski
Maria Prośniewska
Marcin Serafin
Michał Skoczylas
Wojciech Wiliński
Dariusz Sosnowski
Małgorzata Lipińska
Jarosław Kalinka
Tadeusz Laudański

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl